FEN164

Fenix Innovation Group · Phase 1 active Small molecule

At a glance

Generic name	FEN164
Sponsor	Fenix Innovation Group
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome (PHASE2, PHASE3)
NTI164 in Autism Spectrum Disorder (PHASE3)
Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder. (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FEN164 CI brief — competitive landscape report
FEN164 updates RSS · CI watch RSS
Fenix Innovation Group portfolio CI